Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Amicus Therapeutics, Inc. (FOLD) is looking like an interesting pick, as it just reached a key level of support. FOLD's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
The consensus price target hints at a 43.4% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
'Boring' Amicus Therapeutics Is Making Progress
Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price momentum. Pombiliti+Opfolda's launch is progressing well, with patients switching from both Nexviazyme and Lumizyme.
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales.
Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Amicus Therapeutics focuses on rare diseases like Fabry and Pompe, with Galafold and Pombiliti as main value drivers. Galafold is the only oral treatment for Fabry disease, stabilizing the alpha-Gal A enzyme and capturing significant market share. Pombiliti, combined with Opfolda, treats late-onset Pompe disease, showing strong adoption and receiving multiple awards for its efficacy.
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
